The manufacturing industry is booming, with outsourced manufacturing for pharma development rising to a value of $76 billion by 2030. However, alongside these developments, one of the most difficult challenges posed for the industry is managing ongoing communications and relationships between contract manufacturing organisations (CMO) to optimise external partners.
In light of these rapidly evolving pressures on managing external partnerships, quality, cost and scalability, Pharma IQ have created a post-show report highlighting the most exciting takeaways from the 2019 Pharma Contract Manufacturing Forum.
Download the full report on the right >>
Other key benefits to downloading the full report:
- An overview of the process pain points, with expert commentary on the critical gaps in our external manufacturing network and innovative solutions on how to fill them
- A summary of the key challenges in 2020 and the changes that need to be implemented across the industry in order to meet these challenges
- Key takeaways from the 2019 event
- What does the future hold for Pharma Contract Manufacturing – an overview of the 2020 event
It’s hardly surprising that pharma companies are changing the way they work with external partners, with increasing pressures on quality, cost and scalability determining not only which manufacturers the industry outsources to, but how many partners to take on.
With this in mind, Pharma IQ spoke with Simon Hendry, BD Director, Adare Pharmaceuticals, on the current challenges and best practices of streamlining external networks of CMOs. Hendry, speaks in-depth on the critical success factors you need to uncover in the selection process and how to manage emerging markets, all whilst ensuring quality isn’t compromised.
Download the full interview on the right >>
Other key benefits to downloading the full interview:
- Analysing what changes need to be made over the next 12-24 months to meet the main challenges of the industry
- Understanding the best practices for building a successful CMO partnership
- Exploring what criteria is most valuable to the industry when selecting a CDMO
This guide was put together using insights from individuals working directly on Pharma/CMO relationships. In each case we asked individuals how they would tackle a particular CMO crisis and have collated their insights into this handy guide. Example of a CMO crisis included in this guide is; How would you collect and react fast if a batch was rejected in order to keep the supply chain safe?
With insights from over 50 individuals within the Pharma industry, and accompanied by commentary from Ulrich Ruemenapp, Head of Launch Preparation, Bayer this report will take an in-depth look at the most important components when selecting a CMO, the greatest risks when choosing to outsource and best practises for managing CMO networks.
This report will explore:
- Which Key elements you need to prioritise to allow you to reduce your external partner footprint
- The greatest risks when choosing to outsource
- The characteristics sponsors most value in a CMO
We spoke exclusively with Luiz Barberini, Sr. Operations Manager - External Manufacturing Latin America, Bayer about how he manages relationships with contract manufacturers.
From this discussion we have put together this handy pocket guide which covers topics including conflict management, mitigating risks and building resourceful and lasting relationships with contractors.
When building a resourceful and reliable relationship with a CMO it is critical that both companies understand each other’s culture, mission and values. Pharma IQ caught up with Christophe Stevens, Associate Director External Manufacturing, UCB and Christophe Defrance, External Manufacturing Director, UCB to discuss the optimisation and consolidation of their extensive CMO network.
We have put together a handbook of exclusive information on some of the most pertinent issues facing the sector. This handbooks draws on the discussions of leading experts and real-life experiences shared at the Pharma Contract Manufacturing conference, and will serve as a guide to navigating the challenges of Pharma/CMO relationships and best practises for building long-lasting strategic partnerships for the future.
Nowadays, nearly 80% of drugs currently FDA approved on behalf of small bio/pharma companies are contract manufactured, and 50% of products supported by mid-size companies use a CMO. In the lead up to the Pharma Contract Manufacturing Conference, Pharma IQ have looked at the evolution of the roles of CMOs and CDMOs in the industry, and what the future will bring for these organisations.